top of page

AVTE

Aerovate Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$161.1M

Burn Rate (Qtr)

$5.7M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

AVTE

BPIQ_Logo_RGB-01.jpg

Company Profile

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Recent Posts

See what the community is saying - click to see full post.

bottom of page